Rigel Pharmaceuticals Inc... (RIGL)
NASDAQ: RIGL
· Real-Time Price · USD
28.29
-0.41 (-1.43%)
At close: Sep 26, 2025, 11:06 AM
-1.43% (1D)
| Bid | 24.51 |
| Market Cap | 507.36M |
| Revenue (ttm) | 267.92M |
| Net Income (ttm) | 97.82M |
| EPS (ttm) | 5.43 |
| PE Ratio (ttm) | 5.21 |
| Forward PE | 8.36 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 32.44 |
| Volume | 140,324 |
| Avg. Volume (20D) | 602,849 |
| Open | 28.61 |
| Previous Close | 28.70 |
| Day's Range | 28.12 - 29.00 |
| 52-Week Range | 13.57 - 43.72 |
| Beta | 1.27 |
| Ex-Dividend Date | n/a |
About RIGL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RIGL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RIGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRigel Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+22.98%
Rigel Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
4 months ago
+1.15%
RIGL stock has given up its prior gain. Rigel Pharmaceuticals shares were trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.
18 hours ago · seekingalpha.com
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial ExpansionRigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing re...
